Saturday 17 October 2026
Export TMDX’s income statement to Excel — free account
TransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 20.7%, EPS fell 59.2%, free cash flow fell 87.6% and total debt rose 68.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
70.78
5.74
−7.50%
Follow TMDX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 4 | 4 | 3 | 3 | 6 | 7 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.27 | 21.80 |
P/S ratio |
2.09 | 2.09 | 2.09 | 11.44 | 19.17 | 17.49 | 18.06 | 10.34 | 4.69 | 6.83 |
Altman Z-Score |
— | — | — | (1.46) | 3.12 | 0.25 | 10.73 | 2.69 | 2.70 | 5.32 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.96 |
Altman Z″-Score (non-manufacturers) |
— | — | (25.87) | (6.97) | (1.62) | (6.95) | 1.21 | 1.89 | 2.40 | 4.04 |
Beneish M-Score |
— | — | — | (2.12) | (2.46) | 2.05 | (0.04) | (1.21) | (1.95) | (1.32) |
P/Operating CF |
(4.36) | (4.36) | (4.36) | (37.17) | (68.87) | (79.59) | (418.33) | 300.74 | 105.37 | 119.82 |
P/B ratio |
0.00 | 0.00 | 0.00 | 4.94 | 4.73 | 7.80 | 9.01 | 18.20 | 9.06 | 8.74 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 4.94 | 4.73 | 7.80 | 9.01 | 20.33 | 9.64 | 9.00 |
EV/Sales |
3.51 | 3.51 | 3.51 | 9.47 | 15.62 | 15.59 | 16.55 | 10.80 | 5.09 | 6.87 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.24 | 30.64 |
EV/Operating CF |
(1.98) | (1.98) | (1.98) | (6.92) | (13.24) | (16.35) | (33.76) | (200.39) | 46.03 | 21.57 |
EV/FCF |
(1.95) | (1.95) | (1.95) | (6.89) | (13.04) | (14.57) | (26.80) | (13.59) | (27.76) | 31.14 |
Quick Ratio |
— | 2.35 | 1.89 | 5.41 | 11.15 | 4.23 | 9.67 | 8.34 | 7.25 | 6.41 |
Current Ratio |
— | 3.12 | 2.77 | 6.21 | 12.36 | 5.11 | 10.66 | 9.30 | 8.30 | 7.14 |
Net Debt/EBITDA |
0.00 | 0.81 | (0.69) | 1.64 | 3.67 | 1.52 | 5.04 | (5.42) | 3.02 | 0.18 |
Debt/Assets |
— | 0.00% | 79.87% | 32.43% | 22.80% | 26.09% | 21.70% | 71.70% | 63.34% | 47.96% |
Debt/Equity |
— | 0.49 | (5.88) | 0.62 | 0.33 | 0.52 | 0.32 | 3.69 | 2.23 | 1.08 |
Asset Turnover |
0.00 | 0.19 | 0.62 | 0.32 | 0.20 | 0.21 | 0.45 | 0.49 | 0.58 | 0.65 |
Operating CF/Net income |
1.01 | 1.11 | 1.09 | 0.96 | 1.05 | 0.65 | 1.26 | 0.52 | 1.38 | 1.01 |
Capex/Depreciation |
0.00 | 0.00 | (0.54) | (0.13) | (0.29) | (1.94) | (3.42) | (21.90) | (6.57) | (2.18) |
Interest Coverage |
(42.61) | (29.78) | (7.44) | (6.80) | (6.62) | (10.18) | (8.44) | (2.66) | 2.60 | 7.88 |
| 0.00% | 11.54% | 13.16% | 48.76% | (36.27%) | (51.49%) | (28.39%) | (15.42%) | 19.39% | 54.24% | |
| 0.00% | (52.61%) | (112.70%) | (45.50%) | (22.34%) | (30.82%) | (17.59%) | (5.09%) | 4.70% | 20.33% | |
ROIC |
— | 0.00% | (164.13%) | (228.22%) | (127.77%) | (232.50%) | (42.41%) | (7.22%) | 5.84% | 13.65% |
Return on Tangible Assets |
0.00% | (81.35%) | (92.38%) | (37.83%) | (20.59%) | (41.99%) | (14.62%) | (3.97%) | 4.90% | 21.72% |
Average Days of Receivables |
0.00 | 43.93 | 96.40 | 101.43 | 97.72 | 71.57 | 107.83 | 96.04 | 80.78 | 50.81 |
Research and Development Expense of Revenue |
251.84% | 194.63% | 104.91% | 84.18% | 73.45% | 73.70% | 28.69% | 26.18% | 12.68% | 11.40% |
Selling, General and Administrative Expense of Revenue |
127.06% | 95.98% | 94.61% | 99.97% | 94.34% | 126.51% | 74.79% | 49.48% | 38.19% | 30.58% |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 1.11% | 3.62% | 9.42% | 22.73% | 11.04% | 8.19% | 7.52% | 6.09% |
Graham Net Nets |
(0.67) | (0.67) | (0.67) | 0.18 | 0.20 | 0.10 | 0.10 | (0.02) | (0.04) | 0.01 |
Graham Number |
0.00 | 0.00 | 235.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.87 | 41.80 |
Earnings Yield |
(83.78%) | (83.78%) | (83.78%) | (33.56%) | (6.03%) | (8.40%) | (2.19%) | (1.00%) | 1.72% | 4.59% |
Free Cash Flow Yield |
(86.10%) | (86.10%) | (86.10%) | (12.02%) | (6.25%) | (6.12%) | (3.42%) | (7.69%) | (3.91%) | 3.23% |
Revenue per Share |
0.31 | 0.39 | 9.58 | 1.66 | 1.04 | 1.10 | 3.16 | 7.43 | 13.29 | 17.81 |
Operating CF per Share |
(1.21) | (1.16) | (19.12) | (2.27) | (1.23) | (1.05) | (1.55) | (0.40) | 1.47 | 5.67 |
Capex per Share |
0.00 | 0.00 | (0.31) | (0.01) | (0.02) | (0.13) | (0.40) | (5.51) | (3.90) | (1.74) |
Free Cash Flow per Share |
(1.21) | (1.16) | (19.43) | (2.28) | (1.24) | (1.17) | (1.95) | (5.91) | (2.44) | 3.93 |
Cash per Share |
0.00 | 1.24 | 14.89 | 5.68 | 5.09 | 3.35 | 6.81 | 12.14 | 10.13 | 14.37 |
Shareholders Equity per Share |
0.00 | 0.89 | (4.21) | 3.85 | 4.21 | 2.46 | 6.34 | 4.22 | 6.88 | 13.92 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.89 | (4.21) | 3.85 | 4.21 | 2.46 | 6.34 | 4.22 | 6.88 | 13.92 |
Free Cash Flow |
(24.19) | (23.10) | (26.40) | (32.45) | (30.72) | (32.38) | (57.72) | (192.09) | (80.94) | 133.59 |
Working Capital |
— | 23.14 | 22.24 | 83.89 | 134.89 | 95.47 | 228.63 | 455.72 | 437.30 | 548.48 |
Capital Expenditures |
(1.48) | (0.26) | (0.42) | (0.16) | (0.45) | (3.52) | (11.91) | (179.06) | (129.74) | (59.25) |
Net Current Asset Value |
— | 14.83 | (13.09) | 49.35 | 98.63 | 51.67 | 162.52 | (58.19) | (78.26) | 42.51 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 59.91 | 38.31 |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.01 | 0.02 | 0.12 | 0.13 | 0.74 | 0.29 | 0.10 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.26 | 38.08 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.26 | 0.22 | 0.26 | 0.33 | 0.18 | 0.18 | 0.05 | 0.07 | 0.08 |
Cash ROIC |
0.00% | (45.19%) | (54.79%) | (19.15%) | (11.63%) | (16.56%) | (12.86%) | (18.50%) | (7.53%) | 9.06% |
Accounts Receivable Turnover |
0.00 | 3.52 | 5.97 | 4.72 | 3.82 | 4.73 | 5.57 | 5.30 | 5.47 | 6.65 |
Accounts Payable Turnover |
2.48 | 2.52 | 1.77 | 1.63 | 2.13 | 2.32 | 5.64 | 10.90 | 15.60 | 23.51 |
Inventory Turnover |
1.78 | 1.81 | 0.84 | 0.95 | 0.78 | 0.68 | 1.59 | 2.70 | 3.95 | 5.09 |
Average Days of Payables |
68.38 | 222.04 | 236.55 | 271.55 | 48.89 | 266.68 | 43.26 | 53.03 | 20.93 | 15.57 |
Days of Inventory on Hand |
(102.18) | 503.53 | 464.93 | 420.27 | 483.78 | 595.80 | 266.82 | 184.46 | 94.69 | 73.52 |
Average Receivables |
— | 2.18 | 2.18 | 5.00 | 6.71 | 6.40 | 16.77 | 45.59 | 80.65 | 91.00 |
Average Payables |
2.29 | 2.29 | 4.12 | 5.98 | 4.23 | 3.93 | 5.00 | 8.03 | 11.50 | 10.32 |
Average Inventory |
3.19 | 3.19 | 8.62 | 10.25 | 11.58 | 13.40 | 17.73 | 32.42 | 45.39 | 47.72 |
Average Assets |
— | 39.58 | 21.08 | 73.73 | 128.66 | 143.46 | 206.02 | 491.60 | 755.06 | 936.22 |
Average Common Equity |
— | (180.48) | (180.48) | (68.80) | 79.27 | 85.87 | 127.61 | 162.29 | 182.90 | 350.85 |
Columns are period end dates